Plain-English translation of NCT06511050 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing lumbrokinase, a natural enzyme derived from earthworms, to see if it can help adults who are struggling with long-lasting symptoms from three different conditions: Long COVID (ongoing symptoms after COVID-19), post-treatment Lyme disease syndrome (persistent symptoms after Lyme disease treatment), or myalgic encephalomyelitis/chronic fatigue syndrome (severe fatigue and related symptoms). Researchers want to understand whether this medication is safe and might help people feel better when they take it twice daily for 6 weeks.
Many people experience chronic, debilitating symptoms long after an acute infection or illness, and current treatment options are limited. This trial exists to explore whether this medication—which has been used in some parts of the world—might help restore quality of life for people living with these exhausting, long-term conditions.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will take capsules of the medication twice per day for 6 weeks. You will visit the research site at the beginning of the study and again at the end to have your health and symptoms checked. The researchers will ask you questions about how you're feeling and may collect some basic health information to see whether the treatment has helped improve your quality of life.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States